Answers are grounded in this paper and cite their sources.
Sir, Complex regional pain syndrome (CRPS) is a post-traumatic limb pain associated with limb-confined sensory, autonomic, motor, skin and bone changes. Its causes are unknown, although recent studies have suggested an autoimmune contribution [1]. We previously reported success of repeated, pain-contingent, low-dose i.v. immunoglobulin treatments in reducing pain in one patient with severe intractable CRPS [2] and in a small, randomized controlled trial (RCT) we found that a single dose of IVIG reduced pain in patients with 6–30 months CRPS duration [3], but the duration of these effects was variable. To support the development of larger trials we investigated the potential long-term efficacy and cost-effectiveness of immunoglobulin treatment. Between August 2010 and September 2011 we conducted an open, single-centre, proof-of-concept trial (ISRCTN63226217) of immunoglobulin maintenance treatment. Phone follow-up was until 12 months after the final infusion. Eligible patients were 5/12 participants in our earlier RCT, with two or more points less pain after IVIG vs placebo in the RCT [11-point (0–10) numerical rating scale (NRS) [4], IVIG responders], who now had an on-going pain intensity of NRS 5 or higher. Following ethics approval (University College London/University College London Hospital) and written informed consent, we confirmed Budapest clinical criteria [5] and administered a single dose of 1 g/kg IVIG (the priming dose). In choosing this dose we explored whether doubling the previously applied dose of 0.5 g/kg would achieve additional pain relief. For safety reasons we stipulated that the i.v. treatment dose would revert to 0.5 g/kg should treatment of the first two patients with the 1 g/kg dose result in no better pain relief. Patients reporting important pain relief (>30%) were then trained to self-administer weekly one-quarter of their initial IVIG dose using a s.c. immunoglobulin (16% concentration) at home. Treatment with s.c. immunoglobulin is a patient-preferred treatment option that achieves high trough levels [6]. To gauge the lowest effective maintenance dose we halved the s.c. doses after both 6 and 9 months and reinstated the previous dose if this caused an increase in pain. Patients recorded their average daily pain intensities, quality of life and functional outcomes (Table 1; supplementary Table S1, available at Rheumatology Online). We also measured stimulus-evoked pain with a quantitative sensory test (QST). In accordance with published guidelines, patients were supported by an occupational therapist and a psychologist [7]. Information on the power analysis and statistical analysis is available as supplementary data at Rheumatology Online. Patient demographics, disease characteristics and study outcomes Patients’ ages ranged from 43 to 69 years. aConcomitant disorders: patient 1: psoriatic arthritis on MTX, with mild pain, not affecting the CRPS limb, gluten-sensitive enteropathy, pernicious anaemia; patient 2: smoker; patient 3: relapsing-remitting multiple sclerosis, Ehlers–Danlos II, long-standing pituitary microadenoma; patient 4: hypertension, rosacea; F, female; M, male. bFormer participant in the earlier RCT; L, lower limb; LL, both lower limbs; U, upper limb. cPain intensity recorded on an 11-point (0–10) numerical rating scale, with 0 = no pain and 10 = pain as bad as you can imagine [4]; the baseline value (average pain intensity over 14 days after enrolment) is in brackets, followed by the mean values of diary entries on days 6–14 after IVIG treatment, the mean of the entries from the remainder of the trial period (11.5 months in patient 1, 2.5 months in patient 3) and the average pain intensity over the week prior to phone follow-up 12 months after the last s.c. infusion. dThe patient was discharged after the IVIG treatment and did not receive s.c. treatment, therefore no additional data values are available. eEQ-5D: EuroQol score assessing quality of life in five domains (self-care, mobility, usual activities, pain and discomfort, anxiety/depression) at three levels (no problems, moderate/some problems, severe/extreme problems). The values given were taken at the day of enrolment (in brackets), day 14 after the priming infusion and at the end of the study. fPain interference is the previous week’s average pain interference with seven activities of daily living, recorded on an 11-point (0–10) numerical rating scale, with 0 = no interference and 10 = complete interference. The values given were taken at the day of enrolment (in brackets), day 14 after the priming infusion and at the end of the study. gQST BNRS is the quantitative sensory testing brush allodynia pain score, with pain intensity on a 0–10 numerical rating scale after five repeated gentle strokes with a soft brush over the painful area in 1 s intervals; additional QST results are available upon request from the corresponding author. The values given were taken at the day of enrolment (in brackets), day 14 after the priming infusion and at the end of the study.hThis patient’s repeat QST results were not taken due to scheduling issues. N/A, not applicable. Patient demographics, disease characteristics and study outcomes Patients’ ages ranged from 43 to 69 years. aConcomitant disorders: patient 1: psoriatic arthritis on MTX, with mild pain, not affecting the CRPS limb, gluten-sensitive enteropathy, pernicious anaemia; patient 2: smoker; patient 3: relapsing-remitting multiple sclerosis, Ehlers–Danlos II, long-standing pituitary microadenoma; patient 4: hypertension, rosacea; F, female; M, male. bFormer participant in the earlier RCT; L, lower limb; LL, both lower limbs; U, upper limb. cPain intensity recorded on an 11-point (0–10) numerical rating scale, with 0 = no pain and 10 = pain as bad as you can imagine [4]; the baseline value (average pain intensity over 14 days after enrolment) is in brackets, followed by the mean values of diary entries on days 6–14 after IVIG treatment, the mean of the entries from the remainder of the trial period (11.5 months in patient 1, 2.5 months in patient 3) and the average pain intensity over the week prior to phone follow-up 12 months after the last s.c. infusion. dThe patient was discharged after the IVIG treatment and did not receive s.c. treatment, therefore no additional data values are available. eEQ-5D: EuroQol score assessing quality of life in five domains (self-care, mobility, usual activities, pain and discomfort, anxiety/depression) at three levels (no problems, moderate/some problems, severe/extreme problems). The values given were taken at the day of enrolment (in brackets), day 14 after the priming infusion and at the end of the study. fPain interference is the previous week’s average pain interference with seven activities of daily living, recorded on an 11-point (0–10) numerical rating scale, with 0 = no interference and 10 = complete interference. The values given were taken at the day of enrolment (in brackets), day 14 after the priming infusion and at the end of the study. gQST BNRS is the quantitative sensory testing brush allodynia pain score, with pain intensity on a 0–10 numerical rating scale after five repeated gentle strokes with a soft brush over the painful area in 1 s intervals; additional QST results are available upon request from the corresponding author. The values given were taken at the day of enrolment (in brackets), day 14 after the priming infusion and at the end of the study.hThis patient’s repeat QST results were not taken due to scheduling issues. N/A, not applicable. No patient had received immunoglobulin since RCT participation. One patient declined participation and another had developed neoplastic disease and was excluded. Between August 2010 and May 2011 we enrolled three earlier RCT participants. After a protocol change we approached additional patients seen at the study centre over the past 4 years to achieve the required number of four s.c. immunoglobulin-treated patients (supplementary data, power analysis and statistical analysis plan available at Rheumatology Online) and we enrolled one patient in May 2011; however, we stopped ongoing treatments in existing patients and enrolment of new patients in July 2011 after receipt of a post-marketing report of thromboembolic events associated with the s.c. immunoglobulin used (which has since been withdrawn from the UK market). Patients were permitted to use drugs they had remaining at home and the study was stopped thereafter. Two of the treated patients passed the screening stage and received s.c. immunoglobulin treatment over 12 and 3 months, respectively (patient 1: 1 g/kg/4 weeks × 6 months, followed by 0.5 g/kg/4 weeks × 3 months, and 0.25 g/kg/4 weeks × 3 months; patient 3: 0.5 g/kg/4 weeks × 3 months; supplementary Fig. S1, available at Rheumatology Online). The treatment provided sustained pain reduction and improvements in function, quality of life and QST results (Table 1, supplementary Fig. S1 and supplementary Table S1, available at Rheumatology Online). At follow-up in September 2012, 12 months after their final infusion, these two patients had remained in remission. The other two patients experienced no important beneficial effects. Patients documented mild to moderate adverse reactions (Table 1). Cost-effectiveness calculations are provided in supplementary Table S2, available at Rheumatology Online. This is, to our knowledge, the first report both of successful maintenance treatment with immunoglobulin and of induction of long-term remission in very long-standing CRPS. Our study was limited by the lack of a control group and its small size. Both responders had concomitant autoimmune diseases (Table 1), but we previously documented good (single-dose) IVIG efficacy in otherwise healthy patients [3]. Although we stopped the study early due to unexpected side effects reported with the drug in other patients (Methods section), similar reports have not emerged with other s.c. products; what renders the used product unique is unknown. We had previously observed no induction of remission in published [2] or unpublished cases, all treated repeatedly in pain-contingent intervals. It is possible that maintenance of a certain IgG plasma level is required for long-lasting immune modulation, paralleling reports in other disorders [6]. Assuming ongoing pain relief, immunoglobulin treatment was cost effective in our two patients (supplementary Table S2, available at Rheumatology Online). Larger studies are now required to confirm and quantify both the pain-relieving and disease-modifying effects of immunoglobulin maintenance therapy in long-standing CRPS. Low-dose immunoglobulin maintenance treatment induced stable pain reduction in two patients with very long-standing CRPS. Professor G. Sprotte advised on the dosing regimen. Mrs Lynne Wyatt, Walton Centre, Liverpool, contributed to the study management. The authors wish to thank the participating patients and the staff at the Clinical Trials Unit, Walton Centre, Liverpool; and Prof Angela Vincent, Oxford, for suggestions to the manuscript. Funding: This work was supported by the Pain Relief Foundation, Liverpool, CSL-Behring (study drugs and financial support) and the UK National Institute for Health Research (proportional funding from the Study Portfolio). Disclosure statement: J.B. has recently been employed by Baxter.
No takes yet. Share an insight, caveat, or question.
Göebel et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: